Physician profile
Sergio A Sanchez
NPI 1912948647
$29,969.45
in general payments reported to CMS, 2019-2025
20 companies · $5,559 in 2025
The $5,559 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $604 · 2021: $781 · 2022: $834 · 2023: $12K · 2024: $8,650 · 2025: $5,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $3,608 · Travel and Lodging: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,450.00 |
| Food and Beverage | $3,607.97 |
| Travel and Lodging | $967.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24,129.83 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,268.83 | 2020-2025 | Caplyta |
| Abbvie INC. | $899.11 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $535.33 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Allergan, INC. | $477.29 | 2019-2020 | |
| Alkermes, INC. | $390.50 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $362.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $322.20 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $284.35 | 2021-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $276.74 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $253.57 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $137.45 | 2019-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $125.41 | 2019 | |
| Janssen Scientific Affairs, LLC | $124.09 | 2023 | Invega Sustenna |
| Bausch Health US, LLC | $114.99 | 2019-2023 | Aplenzin |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $114.28 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $102.20 | 2024-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $27.36 | 2019 | |
| Eisai INC. | $12.01 | 2021 | |
| Indivior INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.